Herpes simplex virus type 1 infection and glucocorticoid treatment regulate viral yield, glucocorticoid receptor and NF-κB levels

A C Erlandsson, L-G Bladh, P Stierna1, T Yuelc-Lindberg2, O Hammarsten3, T Modéer2, J Harmenberg4 and A-C Wikström

Department of Medical Nutrition, Karolinska Institutet, Novum, S-141 86 Huddinge, Sweden
1ENT, Department of Clinical Science, Huddinge University Hospital, 141 86 Huddinge, Sweden
2Institute of Odontology, Department of Pediatric Dentistry, Karolinska Institutet, 141 86 Huddinge, Sweden
3Department of Clinical Chemistry, Gothenburg University, Sahlgren’s University Hospital, 413 45 Gothenburg, Sweden
4Medivir AB, Lunastigen 7, 141 44 Huddinge, Sweden

(Requests for offprints should be addressed to A-C Wikström; Email: lotta.wikstrom@mednut.ki.se)

Abstract

The interplay between the endocrine and immune systems has come into focus in recent years with the insight that endocrine parameters may affect susceptibility to both auto-immune and infectious diseases. Our interest in immunoendocrine regulation led us to investigate the effects of glucocorticoids on Herpes simplex virus type 1 (HSV–1) infections. Glucocorticoids used to treat inflammatory conditions are not yet recommended for HSV–1 therapy, since they have been reported to prolong viral shedding both in vivo and in vitro. Here we report that glucocorticoids did not alter the viral yield in human gingival fibroblast (HGF) cell culture when glucocorticoid treatment and viral infection occurred simultaneously, but the viral yield increased when cells were treated with the glucocorticoid dexamethasone (dex) prior to viral infection. We found that viral infection in our primary cell system increased NF-κB levels and DNA binding. In addition, the amount of glucocorticoid receptor (GR) increased following viral infection, and HSV–1 infection as such could induce glucocorticoid-driven transcription of a reporter gene in human embryo kidney (HEK) 293 cells stably transfected with GR. Dex treatment did not affect HSV–1-induced binding of p65 to an NF-κB element in an electrophoretic mobility shift assay, and acyclovir was still efficient as an anti-viral drug in the presence of dex. Further studies of the observed effects of HSV–1 infection and glucocorticoid treatment on GR and NF-κB regulation could give insights into the immunoendocrine mechanisms important for defence and therapy against viral infections.

Journal of Endocrinology (2002) 175, 165–176

Introduction

Herpes simplex virus type 1 (HSV–1) causes fever blisters or genital lesions that are the result of both a viral cytopathic effect and a massive inflammatory response. Currently HSV–1 lesions are treated with anti-viral drugs that, if taken orally and in the early phase of the infection, have an inhibitory effect on viral replication but do not counteract the painful inflammation. It has therefore been of interest to treat the lesions with anti-inflammatory substances, for example glucocorticoids. However, this approach is controversial since it has been suggested that glucocorticoid treatment may increase the viral yield in vitro (Harrell & Sydskis 1982, Dreyer et al. 1989), while other reports suggest a decreased viral yield (Notter & Docherty 1978). In PC12 cells differential glucocorticoid effects have been shown to be dependent on both viral replication origin and cellular differentiation (Hardwicke & Schaffer 1997). This may be related to a putative glucocorticoid response element (GRE) in the oriL, one of the two different origins of replication within the HSV–1 genome (Hardwicke & Schaffer 1995). Glucocorticoids have also been shown to have an effect on human immunodeficiency virus type-1 (HIV-1) replication, however, as for HSV–1, the nature of the effects is disputed. Some reports showed a slight increase in HIV-1 replication (Markham et al. 1985, 1986) while others reported an inhibitory effect (Kino et al. 2000). The half–perfect GRE within the HIV-1 long terminal repeat (LTR) promoter (Ghosh 1992) which can bind dimerised and ligand-activated glucocorticoid receptor (GR), may play a role in glucocorticoid effects on HIV-1 replication. Kino and co-workers (2000) suggested that the inhibitory effect of glucocorticoids on the HIV-1 LTR may be exerted via non-GRE-dependent inhibition of the strongly positive host transcription factor NF-κB or by competition with/
squelching of other transcription factors. In Kino et al.’s experiments glucocorticoids suppressed, rather than stimulated, the HIV-1 promoter. In cases where an increased viral replication is obtained it may be due to glucocorticoid-mediated immunosuppression of the host.

Glucocorticoids mediate their effects by binding to the intracellular GR (reviewed in Adcock 2000 and Newton 2000). In the absence of ligand GR is sequestered in the cytoplasm, bound to several other proteins in a multi-protein complex. The receptor is a ligand-activated transcription factor that upon activation is released from the multiprotein complex and translocates to the nucleus where it binds as a homodimer to specific recognition sequences, called GREs. The GR is important in the regulation of several target genes involved in a broad spectrum of vital physiological processes. Glucocorticoids can act as potent anti-inflammatory agents as they repress the expression of cytokines, adhesion molecules and enzymes involved in the inflammatory process (Barnes & Adcock 1993). The anti-inflammatory effects of glucocorticoids are largely considered to be exerted via cross-talk with pro-inflammatory signalling pathways via protein–protein interactions. Of special interest is the interaction with NF-κB, which is a pro-inflammatory transcription factor important in the early cellular response to pathogens and which acts to promote inflammation (Barnes & Karin 1997). NF-κB and GR mutually antagonise the effects of one another and hereby glucocorticoids can act in an anti-inflammatory way (Caldenhouen et al. 1995). In a normal cell NF-κB is retained in the cytoplasm by an inhibitory protein, IκB. In response to a variety of stimuli including viral and bacterial pathogens, cytokines and stress activators, the cytoplasmic NF-κB pathway is activated. The IκB protein is then phosphorylated and thereby destined for subsequent degradation (Baldwin 1996). The released and activated NF-κB dimer translocates to the nucleus and regulates transcription of target genes by binding to specific NF-κB sites in DNA.

Like many viruses, HSV-1 influences cellular host mechanisms in order to promote its own propagation. HSV-1 has been shown to induce the pro-inflammatory mediator NF-κB (Rong et al. 1992, Patel et al. 1998, Amici et al. 2001). The persistent nuclear translocation of NF-κB in HSV-1 infected cells has been further shown to coincide with increased binding of NF-κB to specific DNA response elements (Patel et al. 1998). Whether the increased DNA-bound NF-κB reflects increased activity and subsequent transcription of target genes is not clear, as Patel et al. (1998) report decreased expression of a reporter gene, while others report increased transcription (Rong et al. 1992, Amici et al. 2001). Although increased GR expression or activity has not been reported in response to HSV-1 infection, other pathogens have been shown to mediate increased GR activity. Tomita and co-workers (1985) reported that human lymphocytes transformed with Epstein-Barr virus showed both increased concentration and number of glucocorticoid binding sites as compared with non-transformed cells. Further, HIV is thought to mediate increased GR activity via the viral protein Vpr, which acts as a coactivator for GR, and thereby upregulates transcription of GR-dependent genes (Refaeli et al. 1995, Kino et al. 1999).

To further study the effects of glucocorticoids on HSV-1 infection we used primary gingival fibroblasts, an untransformed cell line that can be considered to be a natural target for HSV-1 infection. Dexamethasone (dex) treatment prior to infection (pre-treatment) increased viral yield, whereas dex co-treatment had no impact on viral yield. As we found that glucocorticoid treatment had differential effects on the viral yield depending on the timing of the glucocorticoid treatment we were interested to investigate how HSV-1 infection, with or without glucocorticoid treatment, affected two proteins central in the control of inflammatory and anti-inflammatory events, GR and NF-κB. We found, as previously reported for HSV-1 infection in a variety of cell lines, that the nuclear expression of NF-κB in our primary cell culture was upregulated in response to HSV-1 infection and that binding of an NF-κB element in an electromobility shift assay (EMSA) was induced. In addition to the increased nuclear NF-κB expression, we also observed a nuclear translocation and an increase in GR protein levels that has not previously been reported in HSV-1 infected cultures. We also found that HSV-1 infection could lead to an increased glucocorticoid-driven reporter gene activity in GR-deficient human embryo kidney cell line 293 (HEK 293) stably transfected with GR. Furthermore, dex treatment prior to infection led to lower levels of GR, being detected from the time of infection up to 24 h post-infection (p.i.), as compared with the high GR levels in infected, untreated or infected, co-treated cells. We suggest that up-regulation of GR may be one factor of importance in the defence against HSV-1 infection.

Material and Methods

Cells and virus

Human primary gingival fibroblasts (HGF) were obtained from gingival biopsies from healthy volunteers, a procedure approved by the ethical committee at Huddinge University Hospital. The fibroblasts were propagated in high glucose Dulbecco’s modified Eagle medium (DMEM, GibcoBRL Laboratories Inc., Gaithersburg, MD, USA), supplemented with 8% foetal bovine serum (FBS) (Sigma Chemical Co., St Louis, MO, USA), 100 µg/ml streptomycin and 100 U/ml penicillin (GibcoBRL Laboratories Inc.) at 37 °C in 5% CO₂.

African green monkey kidney cells (Vero cells; a gift from the Swedish Institute for Infectious Disease Control, Solna, Sweden) were propagated in Earl’s modified Eagle medium (GibcoBRL Laboratories Inc.) supplemented as
Vero cells were plated in 24-well multidishes at a density of 70% confluence a share of the flasks were pre-treated with 1 µM dex (Sigma Chemical Co.). After 24 h incubation the confluent cells were washed twice in PBS and inoculated with the C42 p2 strain, of HSV-1 diluted in serum-free medium, at a multiplicity of infection (MOI) of 10⁻³ plaque-forming units (pfu)/cell for protein isolation. After 1 h of adsorption at 37 °C in 5% CO₂, serum-supplemented medium containing either 1 µM acyclovir (ACV, Sigma Chemical Co.), 1 µM dex or a combination of the two was added to cells either pre-treated or not pre-treated with dex. Cells were incubated for an additional 24 h and supernatants were then removed and frozen at −80 °C for further analyses in the plaque assays. The cells were harvested for protein isolation (see below).

Plaque assay
Vero cells were plated in 24-well multidishes at a density of 2 × 10⁵ cells/well 72 h prior to dex pre-treatment. At 70% confluence a share of the flasks were pre-treated with 1 µM dex (Sigma Chemical Co.). After 24 h incubation the confluent cells were washed twice in PBS and inoculated with the C42 p2 strain, of HSV-1 diluted in serum-free medium, at a multiplicity of infection (MOI) of 10⁻³ plaque-forming units (pfu)/cell for further analysis of viral yield, or MOI of 3 pfu/cell for protein isolation. After 1 h of adsorption at 37 °C in 5% CO₂, serum-supplemented medium containing either 1 µM acyclovir (ACV, Sigma Chemical Co.), 1 µM dex or a combination of the two was added to cells either pre-treated or not pre-treated with dex. Cells were incubated for an additional 24 h and supernatants were then removed and frozen at −80 °C for further analyses in the plaque assays. The cells were harvested for protein isolation (see below).

Cytosol and nuclear extract preparation
HGF cell cultures were harvested by scraping and subsequently pelleted by centrifugation. The cell pellets obtained were resuspended in buffer (10 mM Hepes pH 7.9, 1.5 mM MgCl₂, 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF) and left on ice for 15 min. The suspensions were subsequently centrifuged for 30 s at 13 000 g at 4 °C. The cytosol fractions were decanted and the remaining pellets were dissolved in a high salt buffer (20 mM Hepes pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl₂, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF) and left on ice for 20 min. The suspensions were subsequently centrifuged for 5 min at 13 000 × g at 4 °C.

**Virus infection**
HGF cells were seeded in 75 cm² flasks at a density of 7.10⁵ cells/flask 72 h prior to dex pre-treatment. At 70% confluence the confluent cells were washed twice in PBS and inoculated with the C42 p2 strain, of HSV-1 diluted in serum-free medium, at a multiplicity of infection (MOI) of 10⁻³ plaque-forming units (pfu)/cell for further analysis of viral yield, or MOI of 3 pfu/cell for protein isolation. After 1 h of adsorption at 37 °C in 5% CO₂, serum-supplemented medium containing either 1 µM acyclovir (ACV, Sigma Chemical Co.), 1 µM dex or a combination of the two was added to cells either pre-treated or not pre-treated with dex. Cells were incubated for an additional 24 h and supernatants were then removed and frozen at −80 °C for further analyses in the plaque assays. The cells were harvested for protein isolation (see below).

**Plaque assay**
Vero cells were plated in 24-well multidishes at a density of 2 × 10⁵ cells/well 72 h prior to infection. At confluence, the cells were inoculated with the viral HGF supernatants (see above), diluted in serum-free medium, and subsequently incubated for 1 h for virus adsorption. The cells were washed in PBS and fresh medium supplemented with 10% FBS and 2 mg/ml human immunoglobulin was added (Beriglobin, Centeon Pharma GmBh, Marburg, Germany). The infection proceeded for 3 days, after which cells were stained with 70% crystal violet (Sigma) in ethanol and plaques were counted. Results are shown as pfu/ml.

**Cytosol and nuclear extract preparation**
HGF cell cultures were harvested by scraping and subsequently pelleted by centrifugation. The cell pellets obtained were resuspended in buffer (10 mM Hepes pH 7.9, 1.5 mM MgCl₂, 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF) and left on ice for 15 min. The suspensions were subsequently centrifuged for 30 s at 13 000 g at 4 °C. The cytosol fractions were decanted and the remaining pellets were dissolved in a high salt buffer (20 mM Hepes pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl₂, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF) and left on ice for 20 min. The suspensions were subsequently centrifuged for 5 min at 13 000 × g at 4 °C.

**NF-κB and GR expression: SDS-PAGE and Western blot**
Protein concentrations were determined in a Bradford assay (BioRad). Equal amounts of total protein were run on SDS-PAGE (9% polyacrylamide gel) under reducing conditions and blotted to polyvinylidene difluoride membrane (BioRad). The membranes were subsequently protein-stained with ponceau solution (Sigma) for confirmation of successful, and equal, protein transfer and equal protein amounts. The membranes were further destained in PBS. After blocking with 5% defatted dry milk, the membranes were incubated with primary antibodies directed against either GR (sc-1003, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) or p65 (sc-109, Santa Cruz Biotechnology Inc.), diluted in PBS and 1% defatted dry milk for 1.5 h at room temperature. After washing in PBS with 0.5% Tween 20, the polyvinylidene difluoride membranes were incubated with horseradish peroxidase-conjugated secondary antibody (Amersham Pharmacia Biotech), diluted in PBS and 1% defatted dry milk for 1 h at room temperature. The membranes were again washed in PBS and incubated with Supersignal WestFemtoMaximumSensitivitySubstrate (Pierce, Rockford, IL, USA) for 5 min. The chemiluminescence signals were detected and semi-quantified in a Fuji LAS-1000 image analyser.

**GR transactivation activity: transient transfection and GRE-luciferase reporter assay**
1 × 10⁶ cells of each HEK cell clone (293wt and 293-GR) were seeded into two separate 25 cm² cell culture flasks and incubated overnight at 37 °C in 5% CO₂. The cells were transfected with 1 µg of the previously described (GRE)₅tk-luciferase (luc) (Schule et al. 1988) reporter plasmid diluted in serum-free medium using lipofectine (GibcoBRL Laboratories Inc.). After 6 h of incubation, culture medium was added and the cells were incubated overnight at 37 °C in 5% CO₂. The semi-adherent cells were collected in serum-free media in two separate tubes, each cell suspension was divided into two separate tubes and centrifuged at 1600 g for 5 min. The cell pellets were resuspended in serum-free media, the cell suspensions recentrifuged at 1600 g for 5 min and the supernatants withdrawn. Each cell pellet was diluted in either 1 ml of
NF-κB DNA-binding: EMSA

Nuclear extracts were prepared as described above. Nuclear extract containing 4–8 µg total protein was added to a 20 µl binding reaction containing 20 mM HEPES pH 7.8, 5 mM MgCl2, 100 mM KCl, 20% glycerol, 0.1% Triton X-100 and 0.1–0.3 ng 32P-labelled oligonucleotide corresponding to the NF-κB binding site from the human intercellular adhesion molecule-1 (ICAM-1) gene promoter (upper strand 5’ GGA TTC TGG AAA TTC CCT TT 3’). A control experiment was performed inducing NF-κB binding activity by treating HGF cells with tumour necrosis factor (TNF)-α (200 U/ml) (Roche Diagnostics Scandinavia AB, Bromma, Sweden) for 1 h before preparing nuclear extract as described above. Supershifts were conducted by including 2 µl of the p50 antibody sc-114 or the p65 antibody sc-109X (Santa Cruz Biotechnology Inc.) in the binding reaction. Specific and non-specific competition experiments were performed by including a 100-fold excess of non-labelled consensus oligonucleotide or the consensus oligonucleotide mutated at one base. The reactions were incubated for 20 min at room temperature and subsequently run on PAGE (4% polyacrylamide, 0.25 × TBE (90 mM Tris–borate, 2 mM EDTA), 0.01% NP-40). After electrophoresis the gels were dried and autoradiographed.

Results

Pre-treatment with dex up-regulated herpes simplex viral yield in human gingival fibroblasts

There are conflicting reports in the literature regarding the effects of glucocorticoids on HSV-1 replication and viral yield. We investigated the effect of the synthetic glucocorticoid, dex, on HSV-1 infection in confluent HGF cells.

We used a low MOI (10−3 pfu/cell), to mimic the in vivo situation of the natural HSV-1 infection. The viral yield was measured at 24 h p.i. in a Vero cell viral plaque assay. The time point was chosen to correspond to the viral production after one cycle of viral replication in a primary cell. When adding dex at the time of infection we did not observe any effect on viral yield compared with control cells where dex was not added. However, an increased virus production occurred when we pre-treated proliferating cells with dex 24 h prior to HSV-1 infection (Fig. 1). This result was obtained in several independent experiments. We concluded that dex treatment either had no effect on viral yield or increased viral yield as a consequence of the point at which it was added.

GR as well as NF-κB is up-regulated in response to HSV-1 infection of HGFs

HSV-1 infection has been shown to cause persistent nuclear translocation of NF-κB (Patel et al.) and this is considered to be essential for efficient viral replication. As GR and NF-κB serve as mutual antagonists in inflammatory reactions (Barnes & Adcock 1993, Caldenhoven et al. 1995) we were interested to study first if NF-κB translocation also occurred in HSV-1 infected HGF cells and furthermore, to see whether GR was also affected. Figure 2 shows a representative result from several such experiments. Western blotting was performed on cytosolic and nuclear extracts, probing the same extract for p65 – a subunit of the NF-κB dimer – and for GR. By using the same protein amount in all cytosolic and nuclear extracts we could perform semi-quantitative estimations of p65 and

![Figure 1](https://example.com/viral-yield.png)

**Figure 1** Viral yield in dexamethasone (dex) treated human gingival fibroblasts (HGFs). HGFs were untreated (−), co-treated (Co-T) with dex concurrent with, or pre-treated (Pre-T) with dex prior to, infection with herpes simplex virus type 1 (HSV-1, 10−3 plaque-forming units (pfu)/cell) for 1 h at 37 °C. At 24 h post infection (p.i.) viral supernatants were removed and diluted to be assayed for pfu content by plaque assay.
GR levels within the same experiment (Materials and Methods). The p65 and GR levels in cytosol and nucleus after 6, 9 and 12 h p.i. (data not shown) were similar to the levels at 15 h. HSV-1 infection resulted in a slight up-regulation of p65 as well as an increase in the nuclear localisation of p65, most notably at 24 h p.i., as compared with the amount in mock infected HGF cells (Fig. 2, compare lanes 10–12 with lanes 7–9 in the lower panel). We also noted an increase in GR protein levels in the cytosol (Fig. 2, compare lanes 4–6 with lanes 1–3 in the upper panel), as well as a GR nuclear translocation with increased levels of GR in the nucleus, also most obvious at 24 h p.i. (Fig. 2, compare lanes 10–12 with lanes 7–9 in the upper panel).

HSV-1 infection transactivates a (GRE)2-tk-luc reporter gene in HEK 293 cells stably transfected with GR.

The increase of GR nuclear expression in HSV-1 infected cell cultures led us to investigate whether GR was activated in response to HSV-1 infection. To determine this, we investigated whether HSV-1 infection led to transactivation of a glucocorticoid-driven reporter gene. In preliminary experiments, where we transfected HGF cells with a GRE-containing reporter gene using lipofectamine, we did not obtain consistent results in terms of transfection efficiency. Instead we used the GR-deficient HEK cell line 293 either as wildtype (293wt) or stably transfected with a full length GR construct (293-GR). The original GR-deficient 293wt as well as the 293-GR cells were transiently transfected with a reporter plasmid containing (GRE)2-tk-luc. The cells were left to recover overnight and subsequently infected with HSV-1 (3 pfu/cell). At 24 h p.i. the cells were lysed and luciferase activity was measured (see Materials and Methods). HSV-1 infection caused an eightfold induction of the (GRE)2-tk-luc reporter gene in 293-GR cells as compared with mock infected cells (Fig. 3). In the original 293wt cells some induction of luciferase activity was noted, albeit at a lower level, probably reflecting a low endogenous amount of GR.
in these cells. In summary HSV-1 infection led to upregulated GR activity in terms of transactivation.

**Effects of dex on NF-kB and GR expression in primary HGFs infected with HSV-1**

As we found that HSV-1 infection caused increased GR expression and could transactivate a GRE-dependent reporter gene, and that dex treatment caused a differential effect on HSV-1 viral yield depending on when dex was added, we were interested to see if there was a subsequent difference in GR and NF-κB localisation and levels in the two cases. Persistent nuclear translocation of NF-κB has been suggested to be necessary for efficient HSV-1 replication. We investigated whether the expression levels and the localisation of NF-κB were altered by dex administration either at the time of infection (co-treatment) or 24 h prior to HSV-1 infection (pre-treatment). The nuclear p65 expression in HSV-1 infected, dex-co-treated cells (Fig. 4A, lanes 10–12), as well as in pre-treated cells (Fig. 4B, lanes 10–12) was similar to that observed in non-treated HSV-1-infected cells (Fig. 2, lanes 10–12). The addition of dex to HSV-1 infected cells did not affect the ability of NF-κB to translocate, regardless of the time of dex administration. As neither expression nor nuclear translocation of NF-κB was altered, we were interested to study the effects of dex on the NF-κB opposing GR protein in this system. Dex treatment of mock infected cultures down-regulated the GR expression in accordance with previous studies (Dong et al. 1988, Erdeljan et al. 2001, Holloway et al. 2001). This down-regulation was time-dependent as dex-co-treated cells, when assayed at 15–24 h p.i., expressed higher levels of GR in both cytosol and nucleus compared with dex pre-treated cultures which had been exposed to dex for a period of 24 h prior to the measurements (compare Fig. 4A lanes 1–3 with Fig. 4B lanes 1–3 and Fig. 4A lanes 7–9 with Fig. 4B lanes 7–9 respectively). However, the dex treatment resulted in a slight decrease in GR expression in the co-treated cells and a marked decrease in the pre-treated cells, when
compared with untreated cells (compare Fig. 4A and B lanes 1–3 and 7–9 with Fig. 2 lanes 1–3 and 7–9). HSV-1 infection led to an increased level of GR in dex treated cells. However, the increase differed between the pre-treated and the co-treated cells. In co-treated cells infected with HSV-1, the up-regulation of both cytosolic and nuclear GR expression was similar to that observed in non-treated HSV-1-infected cells (compare Fig. 4A lanes 4–6 and 10–12 with Fig. 2 lanes 4–6 and 10–12), whereas the pre-treated cells did not upregulate GR to a similar extent (compare Fig. 4A lanes 4–6 and 10–12 with Fig. 4B lanes 4–6 and 10–12). From this experiment we could conclude that dex treatment of HGF cells prior to HSV-1 infection, which we previously found led to an increased viral yield (Fig. 1), mainly affected the level and intracellular localisation of GR but not of p65. HSV-1 infection caused an up-regulation and nuclear translocation of p65 in HGF cells regardless of dex pre- or co-treatment. In contrast, the overall GR level was reduced and the nuclear translocation was both decreased and delayed in HSV-1-infected, dex-pre-treated, cells.

The DNA binding of NF-κB is increased in HSV-1 infected cells

To further clarify the importance of interplay between NF-κB and GR in relation to viral replication in a primary cell culture we first determined whether the increase of nuclear p65 was associated with an increased binding of p65 to its cognate DNA binding-site. An EMSA analysis of nuclear extracts from HSV-1-infected HGF cells showed increased binding to an NF-κB site corresponding to the one present in the ICAM-1 promoter (Fig. 5A, lanes 4–6). The EMSA analysis resulted in two distinctly retarded complexes in HSV-1 infected cells at 15–24 h p.i. in contrast to the non-infected cells. The late time points were chosen to correspond to the time at which we had observed the increased nuclear expression of p65. Furthermore, we noted a change in the abundance of the two bands over time. At 15 h p.i. the faster migrating complex was dominant (Fig. 5A, lane 4), whereas at 24 h p.i. the slower migrating complex predominated (Fig. 5A, lane 6). The composition of these two complexes with different mobilities was further analysed. Both were specific in the sense that they could be competed for by addition of 100 times excess of the unlabelled ICAM-1 oligonucleotide (Fig. 5A, lane 8), and were unaffected by the addition of 100 times excess of a point-mutated ICAM-1 oligonucleotide (Fig. 5A, lane 9). Furthermore, both complexes contained the two NF-κB subunits, p50 and p65, as they were both supershifted by anti-p50 (Fig. 5A, lane 10) and anti-p65 antibodies (Fig. 5A, lane 11). As proteolysis sometimes gives rise to multiple bands in EMSA experiments, we performed a control experiment using an established NF-κB inducing agent, TNF-α, for comparison. This experiment demonstrated that the faster migrating band observed in the nuclear extracts of HSV-1 infected cells (Fig. 5B, lane 6) corresponded to the NF-κB binding activity in TNF-α treated cells (Fig. 5B, lane 1), rather than to the smaller complex comprising the slower
migrating band. This may indicate that the slower migrating complex could contain additional proteins recruited in response to the HSV-1 infection along with p65 and p50. This notion is further strengthened by the observed increase of the larger complex with time. The recruited proteins may be of viral or cellular origin – ongoing studies will hopefully reveal their identity.

As neither NF-κB expression nor nuclear translocation was affected, although viral yield differed in the two different dex treatments, we were interested to analyse the binding of the ICAM-1, NF-κB element in an EMSA of dex treated cells. Dex treatment has previously been reported not to affect DNA-binding of TNF-α activated NF-κB (Liden et al. 2000). In line with this, DNA-binding of NF-κB in HSV-1-infected HGF cells was not affected by dex. HSV-1 infection induced DNA-binding of NF-κB in both dex co-treated (Fig. 6A lanes 4–6) and pre-treated (Fig. 6B lanes 4–6) cultures in a fashion similar to that in non-treated cells. The same change in abundance of the two distinct bands over time as non-treated cells was noted. This result, in combination with the protein expression data, indicates that glucocorticoid treatment does not affect the virus-induced nuclear translocation of NF-κB, nor the ability of p65 and p50 to bind to DNA.

We suggest that the increase in HSV-1 viral yield caused by dex pre-treatment may be due to a limited availability of GR at the time of HSV-1 infection, meaning that GR could not counteract NF-κB activity. This effect of GR would be expected to occur downstream of the p65 protein expression, nuclear translocation or DNA-binding ability, as all these features are unchanged from the non-treated cases. This is in line with other reports concerning glucocorticoid effects on NF-κB signalling in vivo and in vitro, induced by TNF-α, showing that GR does not disrupt DNA binding by NF-κB (Nissen & Yamamoto 2000).

**Up-regulation of the viral yield in dex pre-treated cultures is abolished by addition of the antiviral agent ACV**

One of the reasons to study glucocorticoid effects on HSV-1 infection is the suggestion that glucocorticoids could be used in clinic to treat herpes simplex-related blisters and inflammation. Therefore we investigated whether an antiviral substance, such as ACV, could still exert its effect of inhibiting viral production when glucocorticoids were present. The HGF cells were pre-treated with either dex or dex in combination with ACV 24 h prior to infection. We used a low MOI (10^{-3} pfu/cell) and measured the viral yield 24 h after infection in a Vero cell viral plaque assay. The low MOI was used to mimic the in vivo situation and we chose this time point as we assumed that it would correspond to the viral production after one cycle of viral replication in a primary cell. We found that ACV in combination with dex could inhibit viral growth to an extent similar to addition of ACV (Fig. 7).

**Discussion**

Herpes simplex virus type 1 infection results in a broad spectrum of symptoms from minor to severe, and very painful, lesions. The majority of the adult population is sero-positive and many infected patients suffer from frequent reactivations, causing discomfort and pain to the individual. The symptoms of the reactivated viral infection are, in part, due to the viral cytopathic effect but mainly to
Glucocorticoids, NF-κB and HSV-1 infection · A C Erlandsson and others

Figure 7 Addition of acyclovir (ACV) inhibits the increased viral yield in HGF cells pre-treated with dex. HGF cells were either untreated or pre-treated with ACV alone or a combination of ACV and dex (Pre-T) 24 h prior to infection with HSV-1 (10^-1 pfu/cell) for 1 h at 37°C. At 24 h p.i. viral supernatants were removed and diluted to be assayed for pfu content by plaque assay. The results are obtained from six individual experiments and are presented as means (± s.d.) fold viral yield compared with untreated control cells.

with HSV-1 led to increased virus production in cells pretreated with dex for 24 h before the infection, but not in cells where dex was added at the time of infection. We used dex at a concentration of 1 µM; high enough to give rise to a significant glucocorticoid-mediated response, but not to inhibit cellular proliferation or cause toxicity in HGF cells (data not shown).

We went on to study the effect of HSV-1 infection on GR itself and found that HSV-1 infection led to up-regulation and nuclear translocation of GR in HGF cells. In another – GR-deficient – cell line, HEK 293-GR, that was transiently transfected with a GR reporter gene, HSV-1 infection led to up-regulated reporter gene activity, without any addition of glucocorticoid. This effect has, to our knowledge, not previously been reported and may indicate that GR regulation is part of the cellular response against viral infections.

Viruses are intracellular microorganisms that take advantage of the host cell machinery to replicate. They have evolved a variety of strategies to target cellular signalling mechanisms to promote their own replication. It has previously been shown that HSV-1 activates several kinases including the c-Jun N-terminal kinase/stress-activated protein kinase (McLean & Bachenheimer 1999, Zachos et al. 1999) and the p38 MAP kinase and transcription factors such as AP-1 (Zachos et al. 1999) and NF-κB (Rong et al. 1992, Amici et al. 2001). Activation of these signalling pathways has been suggested to be important for viral replication. We demonstrated in our study that HSV-1 infection led to increased levels and nuclear translocation of NF-κB in primary HGFs. As we discovered an increased viral yield in cells pre- but not cotreated with dex, a well known inhibitor of NF-κB signalling, we were interested to see whether the NF-κB levels and localisation were regulated differently in cultures pre- and cotreated with dex. We found that dex treatment of HSV-1 infected cells caused up-regulation and nuclear translocation of NF-κB, to a similar extent as in untreated cells, regardless of when the dex was added.

We had seen the effects of HSV-1 on GR levels and signalling and it is known that activated GR usually counteracts NF-κB signalling, so we also examined whether GR expression was differently regulated by pre- or co-treatment with dex. As an added level of complexity in this system, the auto-regulation of GR by glucocorticoids should be taken into consideration. Glucocorticoids generally down-regulate GR expression in most cell types and a low level of GR usually results in limited glucocorticoid responsiveness. Furthermore the auto-regulation of GR is time dependent; after 24 h of glucocorticoid treatment, GR expression was almost undetectable. In HGF cells, dex pre-treatment led to a low GR level at the time of infection. This could be postulated to lead to a diminished ability of GR to counteract NF-κB. Dex co-treated cells, on the other hand, had unaffected levels of GR at the time of infection and the subsequent
infection-induced rise in GR seemed to keep GR levels high throughout the period studied. In cotreated cells, GR would therefore still be expected to counteract the strong NF-κB response in the same fashion as in untreated cells.

We also decided to study the DNA-binding of NF-κB in this system. We found that the increase of nuclear NF-κB in all cases, regardless of when dex was added, led to increased DNA-binding in an EMSA analysis using an NF-κB element from the ICAM-8 promoter. This was similar to that occurring in untreated cells. Whether increased nuclear translocation of NF-κB is in general followed by increased target gene transcription is unclear. Patel and co-workers (1998) have reported transrepression while Amici and co-workers (2001) have suggested that NF-κB is not degraded in response to NF-κB inducing agents, or by treatment with IκB kinase (IKK) inhibitors. As the viral yield is significantly decreased in these studies it has been concluded that nuclear translocation of NF-κB is necessary for efficient viral replication. However, it is not possible to conclude from these studies whether actual NF-κB transactivation activity is required. In this context it should be noted that it has previously been shown that TNF-α-induced NF-κB nuclear translocation and DNA-binding is not affected by dex, but dex still inhibits the transactivation of NF-κB target genes (Liden et al. 2000).

It is possible to explain our findings if we speculate that the DNA-binding of NF-κB, also when induced by viral infection, leads to transactivation of NF-κB regulated genes and that this transactivation is required for viral replication. This NF-κB transactivation could be counteracted by glucocorticoids acting via GR when levels of the receptor are normal, as they are when the cells are non- or cotreated with dex, but not when GR levels are down-regulated by dex pre-treatment. This would not be reflected in differences in NF-κB EMSA patterns in these various cases. Further attempts to study NF-κB transactivation induced by HSV-1 infection in the presence of dex are in progress in our laboratory.

In addition to increased nuclear translocation of NF-κB in response to HSV-1 infection, we also noted that the multiprotein complex binding to the NF-κB recognition sequence changed in composition over time. The binding complexes present in nuclear extracts from HSV-1 infected HGF cells consisted of two sub-populations with different migration abilities in the EMSA. However, both complexes were supershifted by the two anti-NF-κB antibodies used for specificity control, anti-p50 and anti-p65. One explanation may be that the larger complex consists of additional proteins, either of viral or host cellular origin, induced by the infection. Further studies are in progress to determine the nature of these complexes.

The findings in this report also point to a possible explanation for the reactivation of HSV infections by stress. Stress causes an increase of endogenous glucocorticoids that initially activates and then eventually auto-downregulates GR expression (Song et al. 1991, Herman et al. 1995). In the intact organism the multifaceted response to infections involve glucocorticoid release and GR activation, probably to counteract and terminate the defence mechanisms to the infection (reviewed in Mercurio & Manning 1999). Decreased levels of GR could lead to reduced control over NF-κB action. We suggest that the low levels of GR after a stressful event may be one explanation for HSV-1 reactivation.

Although glucocorticoids are considered by many to act permissively for viral infections there are also reports indicating beneficial effects in glucocorticoid treatment of some infections (Wilhelms et al. 1994, O’Brien et al. 1996) and acute respiratory distress syndrome (Meduri et al. 2002). Contrary to the effect of glucocorticoids on HSV-1 replication demonstrated in this report, there exists some experimental evidence that administration of corticosteroids with or without antibiotics may be therapeutic in bacterial infections such as Mycoplasma pulmonis under certain conditions (Bowden et al. 1994). We noted that the GR protein was suppressed to almost undetectable levels after 24 h dex treatment and that this protein was normally upregulated as a consequence of HSV-1 infection. This, and the fact that GR normally counteracts NF-κB, led us to suggest that the lack of sufficient GR may cause increased viral replication. Other host cell factors not identified in this study may, of course, also be of importance.

We tested the concept of anti-viral therapy combined with glucocorticoid adjunct therapy in this system. As we had established the conditions under which viral yield could be expected to be up-regulated, it was possible to study whether the anti-viral drug maintained its efficacy in the presence of dex. By choosing a sub-optimal dose of ACV (1 µM) the system was rendered sensitive to changes in viral yield. Even this low dose of ACV was as efficient when combined with dex as it was alone. 1 µM ACV was sufficient to block the viral replication even in the case of a sixfold increase in the viral yield in response to glucocorticoid treatment.

In summary, we suggest that increased insight into the interplay of various pathogens and immuno-endocrine host responses such as inflammation and GR signalling may be relevant for the development of model systems to test new treatment strategies for viral diseases.
Acknowledgements

We thank M Rönnholm for her excellent technical assistance. This work was supported by the Foundation for Knowledge and Competence, Stockholm, Medivir AB, Stockholm, Åke Wibergs Foundation, Research Foundation of the Karolinska Institutet and Swedish Medical Research Council grants 12557 and KI 13X–281.

References


Tomita M, Chrousos GP, Brandon DD, Ben-Or S, Foster CM, De Vougin L, Taylor S, Loriaux DL & Lipsett MB 1985 Glucocorticoid...
receptors in Epstein-Barr virus-transformed human lymphocytes.

Hormone Metabolism Research

17
674–678.


Received 30 April 2002
Accepted 7 June 2002


ACERLANDSSON and others · Glucocorticoids, NF-κB and HSV-1 infection